PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic. PAION is currently launching remimazolam in the UK and selected further European markets. Remimazolam is partnered in multiple territories outside of Europe. Remimazolam is approved in the U.S., the EU/EEA/UK, China and South Korea for procedural sedation and in Japan and South Korea for general anesthesia.

For more information on the safety of remimazolam, please refer to the EMA Summary of Product Characteristics (SmPC) and is accessible via https://www.ema.europa.eu/en/medicines/human/EPAR/byfavo.